title: Generalised cutaneous necrosis: a complication of low-molecular-weight heparin.
abstract: Subcutaneous low-molecular-weight heparin (LMWH) injections have a predictable dose-dependent anticoagulant effect and have therefore become popular for the prevention and management of thromboembolic diseases. It was initially hoped that use of the smaller molecule and better dose titration would reduce the incidence of side-effects associated with conventional heparin therapy. However, case reports such as this have demonstrated that LMWHs still have the capacity to cause heparin-induced thrombocytopaenia and heparin-induced thrombocytopaenia with thrombosis, as well as heparin necrosis. To our knowledge, this is the first-ever-reported case of heparin necrosis associated with tinazaparin. Heparin necrosis is characterised by widespread life-threatening cutaneous necrosis and systemic thrombosis, in which fatal progression of disease can only be halted by stopping heparin therapy. As heparin necrosis is an uncommon disorder, in this report we focus on the clinical clues that may help woundcare professionals consider and confirm the diagnosis.
authors.affiliation: Welsh Institute of Dermatology, Glamorgan House, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK. patelgk@cf.ac.uk
authors.forename: Girish K
authors.initials: GK
authors.lastname: Patel
authors.forename: Arthur G
authors.initials: AG
authors.lastname: Knight
mesh_terms: D000368:Aged; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects*; D006801:Humans; D009336:Necrosis / Q000139:chemically induced / Q000628:therapy; D012867:Skin / Q000473:pathology*; D000078222:Tinzaparin
chemical_list: D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D000078222:Tinzaparin